ResMed financials
$222.83+0.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B | $2.34B | $2.07B |
| Gross profit | $3.48B | $3.09B | $2.69B | $2.36B | $2.02B | $1.88B | $1.77B | $1.54B | $1.36B | $1.20B |
| Gross margin | 61.6% | 60.0% | 57.4% | 55.8% | 56.6% | 58.9% | 59.8% | 59.0% | 58.2% | 58.1% |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M | $809.7M | $579.3M | $541.8M | $435.9M |
| Net income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M | $315.6M | $342.3M |
| Net margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% | 21.0% | 15.5% | 13.5% | 16.6% |
| Diluted EPS | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 |
| EBITDA | $2.11B | $1.88B | $1.56B | $1.32B | $1.16B | $1.10B | $990.4M | $786.8M | $680.2M | $568.9M |
| Operating cash flow | $1.81B | $1.75B | $1.40B | $693.3M | $351.1M | $736.7M | $802.3M | $459.1M | $505.0M | $422.5M |
| Free cash flow | $1.65B | $1.66B | $1.30B | $573.6M | $216.3M | $634.0M | $706.9M | $390.3M | $442.4M | $360.3M |
| Diluted shares | 146.1M | 147.3M | 147.6M | 147.5M | 147.0M | 146.5M | 145.7M | 144.5M | 144.0M | 142.5M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.47B | $1.21B | $238.4M | $227.9M | $273.7M | $295.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $659.4M | $668.3M | $707.2M | $1.44B | $775.2M | $655.4M |
| Total assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B | $4.73B |
| Total liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B | $1.84B |
| Shareholders' equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B | $2.89B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology